Elsevier

Annals of Oncology

Volume 27, Issue 10, October 2016, Pages 1966-1969
Annals of Oncology

industry corner: perspectives and controversies
Establishing a complementary diagnostic for anti-PD-1 immune checkpoint inhibitor therapy

https://doi.org/10.1093/annonc/mdw288Get rights and content
Under a Creative Commons license
open access

ABSTRACT

The role of tumor PD-L1 expression was investigated across the nivolumab clinical development program. Phase III nivolumab trials have shown that patients with tumors not expressing PD-L1 may benefit; therefore, testing is not required to select patients for therapy. The Dako PD-L1 IHC 28-8 pharmDx assay may be used to determine tumor PD-L1 expression as a complementary and informative test.

Cited by (0)